Neurol. praxi. 2015;16(3):167-170
Fycompa® (perampanel): a novel drug for treating epilepsy
- Centrum pro epilepsie Brno, I. neurologická klinika LF MU a FN u sv. Anny, Brno
Fycompa® (perampanel) is a new drug for difficult to treat focal epilepsy. It is a selective non-competitive antagonist of the AMPA receptor, indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalisations in patients with epilepsy aged 12 years and older. Perampanel has demonstrated efficacy in a broad spectrum of preclinical models of seizures. Clinical trials Phase I and II showed a favourable safety profile and a good tolerability. Three Phase III studies and the follow-up study (up to 4 years) showed that the adjunctive treatment with perampanel at the dose of 4–12 mg/day has significantly improved the seizure control. Mechanism of action of perampanel is different than one of all the others antiepileptic drugs. It can be presumed that it could suppress seizures even in patients with otherwise pharmacoresistant epilepsy. Perampanel is a promising drug for the adjunctive treatment of partial and secondary generalised seizures of adolescents and adults, with good tolerability, low potential for interactions with other drugs and with favourable pharmacokinetics, which enables once-daily drug administration.
Keywords: AMPA receptor antagonist, antiepileptic drug, partial epilepsy, perampanel, refractory epilepsy
Published: June 26, 2015 Show citation
References
- Ben-Menachem E. Medical management of refractory epilepsy - practical treatment with novel antiepileptic drugs. Epilepsia 2014; 55(Suppl. 1): 3-8.
Go to original source... 
Go to PubMed... - Brodie MJ, Kelly K, Stephen LJ. Prospective audits with newer antiepileptic drugs in focal epilepsy: Insights into population responses? Epilepsy & Behavior 2014; 31: 73-76. Go to original source... Go to PubMed...
- French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.Neurology 2012; 79: 589-596. Go to original source... Go to PubMed...
- French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, Laurenza A. Evaluation of adjunctive perampanel in patients with refraktory partial-onset seizures: results of randomized global Phase III study 305. Epilepsia 2013; 54(1): 117-125. Go to original source... Go to PubMed...
- Fuseau E, Templeton D, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel in patients with refraktory partial seizures. Epilepsy Curr 2011; 11(Suppl 1): abstract 1.264.
- Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011; 52: 1331-1340. Go to original source... Go to PubMed...
- Hussein Z, Ferry J, Krauss G, Squillacote D. Demographic Factors and Concomitant Antiepileptic Drugs Have No Effect on the Pharmacodynamics of Perampanel. 64th Annual Meeting of the American Academy of Neurology, New Orleans, USA April 2012; Abstract No: P06.127. Go to original source...
- Laurenza A, Ferry J, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Epilepsy Curr 2012; 12(Suppl 1): abstract 2.231.
- Löscher W, Schmidt D. Epilepsy: perampanel - new promise for refractory epilepsy? Nat Rev Neurol 2012; 8(12): 661-662. Go to original source... Go to PubMed...
- Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012; 78: 1408-415. Go to original source... Go to PubMed...
- Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clément J-F, Wang X, Bagul M, Gee M, Zhu J, Squillacote D. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalised seizures: results from Phase III extension study 307. Epilepsia 2014; 55: 1058-1068. Go to original source... Go to PubMed...
- Rektor I, Krauss GL, Bar M, Biton V, Klapper JA, Vaiciene-Magistris N, Kuba R, Squillacote D, Gee M, Kumar D. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012; 126: 263-269. Go to original source... Go to PubMed...
- Rektor I. Perampanel. A novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures. Expert Opinion on Pharmacotherapy. 2013; 14(2): 225-235. Go to original source... Go to PubMed...
- Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011; 11(2): 56-63. Go to original source... Go to PubMed...
- Rosenfeld W, et al Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study. European Journal of Paediatric Neurology (2015) http://dx.doi.org/10.1016/j.ejpn.2015.02.008. Go to original source... Go to PubMed...
- Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, Squillacote D, Yang H, Zhu J, Laurenza A. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: A pooled analysis of three phase III studies. Epilepsia 2013; 54(8): 1481-1489. Go to original source... Go to PubMed...
- Steinhoff BJ, Hamer H, Trinka E, Schulze-Bonhage A, Bien C, Mayer T, Baumgartner C, Lerche H, Noachtar SA multicenter survey of clinical experiences with perampanel in real life in Germany and Austria.Epilepsy Res. (2014), http://dx.doi.org/10.1016/j.eplepsyres.2014.03.015. Go to original source... Go to PubMed...
- Templeton D. Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist. Epilepsia 2009; 50(Suppl 11): abstract 1.199.